The impact of levodopa on post-stroke depression: the ESTREL-depression-study

Figures

• 

  Figure 1. Study flow chart. Abbreviations: ITT = intention-to-treat, on-treatment analysis = analysis including the participants who took less than 80% of the study drug.

• 

  Figure 2. Forest plot of primary outcome and depression severity. The proportion of depression was measured using different cutoff T-scores of the PROMIS short-form depression-4a at three months, showing the number and proportion of participants for each levodopa and placebo group. Cutoff mild depression = T-score ≥ 55, cutoff moderate depression = T-score ≥ 60, cutoff severe depression = T-score ≥ 70.

• 

  Figure 3. Distribution of the proportion of participants with different levels of depression severity in both treatment groups at 3 months. No depression = T-score < 55, mild depression = T-score ≥ 55 and < 60, moderate depression = T-score ≥ 60 and < 70, severe depression = T-score ≥ 70.

• 

  Figure 4. Sensitivity analysis including all participants regardless of their history of depression. Exploring the proportion of depression using different cutoff T-scores of the PROMIS short-form depression-4a at three months with the number and proportion of participants each for the levodopa and placebo group. Cutoff mild depression = T-score ≥ 55, cutoff moderate depression = T-score ≥ 60, cutoff severe depression = T-score ≥ 70.

• 

  Figure 5. Interaction analysis of participant characteristics and the impact of levodopa on PSD. This interaction analysis shows how participant baseline characteristics are associated with the impact of levodopa on depression three months post-randomization. The median was chosen to convert each continuous numerical variable into a binary format. Abbreviations: FMMA = Fugl-Meyer Motor; LD = levodopa; mRS = modified rankin scale; NIHSS = National Institutes of Health Stroke Scale; PL = placebo.